Ratings Gilead Sciences, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 19:08:18 14/07/2025 BST			5-day change	1st Jan Change
112.03 ^USD	+2.18%		+0.09%	+21.12%

06:05pm	Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025	CI
02:57pm	Global markets live: Tesla, Gilead, Kenvue, Amazon, Bayer…

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	GILEAD SCIENCES, INC.				136B
	ELI LILLY AND COMPANY				712B
	JOHNSON & JOHNSON				378B
	ABBVIE INC.				340B
	NOVO NORDISK A/S				305B
	ROCHE HOLDING AG				259B
	NOVARTIS AG				237B
	ASTRAZENECA PLC				219B
	MERCK & CO., INC.				209B
	AMGEN INC.				159B
	Average				295.34B
	Weighted average by Cap.